CYCN News and Press, Cyclerion Therapeutics Inc. From 11/03/19

The NASDAQ Biotechnology Index (INDEXNASDAQ: NBI ) was in the green last week, soaring from 3,322.49 points on Monday’s (October 28) open to reach 3,442.25 points as of 1:28 p.m. EDT on Friday (November 1), representing a 3.35 percent increase during the week. On Wednesday (October 30...

Shares of Cyclerion Therapeutics (NASDAQ: CYCN ) nosedived on Wednesday (October 30) after the company revealed that its two Phase 2 studies of praliciguat — an “orally available systemic sGC stimulator” — did not meet their primary endpoints. According to a pre...

You win some and you lose some. Unless you're Cyclerion Therapeutics (NASDAQ: CYCN)  -- then you lose twice. Shares of the biotech are down 79% at 12:37 p.m. EDT today after announcing a pair of clinical trial failures for praliciguat, which stimulates a protein involved in the widen...

Thinly traded micro cap Cyclerion Therapeutics (NASDAQ: CYCN ) slumps  68%  premarket on increased volume, albeit on turnover of only 55K shares, after its rare feat of announcing two failed clinical trials at the same time. More news on: Cyclerion Therapeutics, Inc., Healthcare ...

– Study did not reach statistical significance on primary endpoint – – Positive trends on primary and secondary endpoints indicate profile that merits further investigation – – Company intends to pursue out-license of praliciguat fo...

– Study in HFpEF patients did not meet primary endpoint; company discontinuing development of praliciguat in HFpEF – – Conference call to be held at 8:30 a.m. ET today  – CAMBRIDGE, Mass., Oct. 30, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therape...

CAMBRIDGE, Mass., Oct. 08, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company developing soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced upcoming medical meeting prese...

Gainers:  BNED   +7.6% . DPW   +5.0% . RMNI   +3.9% . OTCQB:KSHB   +3.6%.  BCOV   +3.4% . More news on: Barnes & Noble Education, Inc., DPW Holdings, Inc., Rimini Street, Inc., Stocks on the move, Read more ...

Gainers:  Sintx Technologies (NASDAQ: SINT ) +71% . Ruhnn Holding Limited (NASDAQ: RUHN ) +29% . Jaguar Health (NASDAQ: JAGX ) +19% . T2 Biosystems (NASDAQ: TTOO ) +15% . OncoCyte Corporation (NYSEMKT: OCX ) +13% . Libbey (NYSEMKT: LBY ) +13% . Cyclerion Therapeutics (NASDAQ: CY...

CAMBRIDGE, Mass., Sept. 10, 2019 (GLOBE NEWSWIRE) -- Cyclerion Therapeutics, Inc. (Nasdaq: CYCN), a clinical-stage biopharmaceutical company focused on the development of soluble guanylate cyclase (sGC) stimulators for the treatment of serious and orphan diseases, today announced that it wi...